Trial Profile
A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms AURORA
- Sponsors ChemoCentryx
- 21 Mar 2023 Results assessing Plasma biomarkers for clinical response and disease severity identified from Hidradenitis Suppurativa patients presented at the American Academy of Dermatology annual Meeting 2023
- 24 Feb 2022 Status changed from active, no longer recruiting to completed.
- 28 Oct 2020 Primary endpoint has not been met. (Proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.), according to a ChemoCentryx media release.